单位：[1]Department of Pulmonary and Critical Care Medicine, Beijing Luhe Hospital, Capital Medical University,Beijing, China[2]Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-Japan Friendship Hospital National Clinical Research Center of Respiratory Diseases Capital Medical University Tsinghua University–Peking University Joint Center for Life Sciences, Beijing, China
Purpose of review This review summarizes the latest discoveries regarding the use of clinical indicators and biomarkers to guide antibiotic use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and it analyzes the advantages and disadvantages of various indicators and markers. Recent findings For AECOPD patients admitted to emergency departments and medical wards, procalcitonin (PCT)-guided antibiotic therapy reduced antibiotic use without adverse outcomes. In contrast, for severe AECOPD patients admitted to ICUs, PCT-guided antibiotic therapy increased the overall mortality in a 3-month followup period, and antibiotic use was not decreased. Summary PCT is the most promising biomarker to guide antibiotic use in patients with AECOPD. However, patients with severe AECOPD admitted in ICU may not benefit from PCT-guided antibiotic therapy.
基金：
National Science Grant for Distinguished Young Scholars [81425001/H0104]; National Key Technology Support Program from Ministry of Science and Technology [2015BAI12B11]; Beijing Science and Technology Project [D151100002115004]
第一作者单位：[1]Department of Pulmonary and Critical Care Medicine, Beijing Luhe Hospital, Capital Medical University,Beijing, China
通讯作者：
通讯机构：[2]Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-Japan Friendship Hospital National Clinical Research Center of Respiratory Diseases Capital Medical University Tsinghua University–Peking University Joint Center for Life Sciences, Beijing, China[*1]Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-Japan Friendship Hospital National Clinical Research Center of Respiratory Diseases Capital Medical University Tsinghua University–Peking University Joint Center for Life Sciences, Yinghua East Road, Chaoyang District, Beijing, China.
推荐引用方式(GB/T 7714)：
Wang Jinxiang,Cao Bin.Procalcitonin and other markers to guide antibiotic use in chronic obstructive pulmonary disease exacerbations in the era of antimicrobial resistance[J].CURRENT OPINION in PULMONARY MEDICINE.2019,25(2):158-164.doi:10.1097/MCP.0000000000000555.
APA：
Wang, Jinxiang&Cao, Bin.(2019).Procalcitonin and other markers to guide antibiotic use in chronic obstructive pulmonary disease exacerbations in the era of antimicrobial resistance.CURRENT OPINION in PULMONARY MEDICINE,25,(2)
MLA：
Wang, Jinxiang,et al."Procalcitonin and other markers to guide antibiotic use in chronic obstructive pulmonary disease exacerbations in the era of antimicrobial resistance".CURRENT OPINION in PULMONARY MEDICINE 25..2(2019):158-164
：